Tuesday, September 08, 2020 9:52:21 PM
Bravo MD2Trader. I appreciate your post. You obviously have a trader's perspective and a scientific/medical perspective. You see that Aviptadil is the real deal, and have committed to see the investment to its fruition. Tell me, did it surprise you as well that 19 of 21 consecutive critical Covid-19 cases were successfully treated? Patients that were so dire they couldn't even get into the critical trial. Excluded based on their horrible condition. Yet, the compassionate use extension took all comers, without picking and choosing, and healed them one after another.
Consecutive. It still amazes me.
This therapeutic, RLF-100/Aviptadil/SamiVir, is the key to ending deaths from Covid-19. For starters.
Consecutive. It still amazes me.
This therapeutic, RLF-100/Aviptadil/SamiVir, is the key to ending deaths from Covid-19. For starters.
Recent RLFTF News
- MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank • ACCESS Newswire • 03/19/2026 06:35:00 AM
- MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics • ACCESS Newswire • 12/23/2025 06:20:00 AM
- Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics • ACCESS Newswire • 12/15/2025 06:20:00 AM
- Relief Therapeutics Shareholders Approve Business Combination with NeuroX • ACCESS Newswire • 11/14/2025 05:40:00 PM
- Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 • ACCESS Newswire • 10/29/2025 06:20:00 AM
- Micro-Cap Biotech Skyrockets on FDA Pediatric Disease Nod • AllPennyStocks.com • 05/22/2025 04:49:00 PM
